Farmiblastina 50 mg powder for injection solution

Package leaflet: Information for the user

Introduction

Package leaflet: information for the patient

Farmiblastina 50 mg powder for injectable solution

doxorubicin hydrochloride

Read the entire leaflet carefully before you start using this medicine, because it contains important information for you.

• Keep this leaflet, as you may need to read it again.
• If you have any questions, ask your doctor, pharmacist, or nurse.
• This medicine has been prescribed for you only and must not be given to other people, even if they have the same symptoms as you, because it could harm them.
• If you experience any adverse effects, consult your doctor, pharmacist, or nurse, even if they are adverse effects not listed in this leaflet. See section 4.

Leaflet contents

1. What Farmiblastina is and what it is used for
2. What you need to know before using Farmiblastina
3. How to use Farmiblastina
4. Possible side effects
5. How to store Farmiblastina
6. Contents of the pack and other information

l

1. What Farmiblastina is and what it is used for

Farmiblastina is an anticancer antibiotic belonging to the anthracycline group and is used in the treatment of various types of cancers, administered either intravenously or, in some cases, intravesically (direct injection into the organ). Farmiblastina works by inhibiting the cell cycle, thereby preventing the proliferation of cancer cells.

Farmiblastina may be used alone or in combination with other medicines in the treatment of both children and adults with the following types of cancer:

1. Breast cancer
2. Bone sarcomas: malignant tumors in the bones
3. Soft tissue sarcomas: malignant tumors that may affect cartilage, muscles, fat, blood vessels, or other tissues
4. Lung cancer
5. Stomach cancer
6. Lymphomas such as Non-Hodgkin's lymphomas (diseases affecting white blood cells or lymphocytes) and Hodgkin's lymphoma (a disease of the lymphatic system)
7. Thyroid gland cancer
8. Gynecological and genitourinary tumors: tumors in the ovaries, endometrium, testicles, prostate, or bladder
9. Pediatric solid tumors such as rhabdomyosarcoma (cancer arising in soft muscle tissue), neuroblastoma (cancer of immature cells, primarily affecting infants and children), Wilms' tumor (a disease in which malignant cells are found in the kidney), and liver tumors
10. Leukemias (cancers of the bone marrow) such as acute lymphoid leukemia, acute myeloid leukemia, and chronic leukemias
11. Induction of multiple myeloma: a cancer that originates in the white blood cells responsible for producing antibodies, which are essential for the body's defense

Farmiblastina will only be prescribed by a physician experienced in cancer-treating medications.

If you have any questions about how Farmiblastina works or why this medicine has been prescribed for you, please consult your doctor.

2. What you need to know before using Farmiblastina

Do not use Farmiblastina

If you are allergic to the active substance or to other anticancer agents of the same group, or to any of the other components of this medicine (listed in section 6).

Do not use Farmiblastina if administration is intravenous:

• If you have a persistent disorder of your immune system (impaired ability to fight infections or diseases)
• If you have or have had severe liver problems
• If you have severe heart problems (arrhythmias, heart attacks, or heart failure)

Do not use Farmiblastina if administration is intravesical:

• If you have urinary tract infections, bladder inflammation, or blood in the urine.

Warnings and precautions

Talk to your doctor, pharmacist, or nurse before starting to use Farmiblastina.

• If you have or have had heart problems, or if you are receiving or have received radiotherapy in areas near the heart.
• If you have previously received treatment with other anthracyclines.
• If you are taking other medicines that can suppress heart contraction.
• If you are taking other medicines for cancer treatment.
• If your immune system is impaired, meaning you have lost the ability to fight infections or diseases.
• If you have or have had liver problems.
• If you have or have had gout, as doxorubicin may increase uric acid levels.
• If you are pregnant or think you might be pregnant (see details below).
• If you are breastfeeding (see details below).
• If you are male, you must use effective contraceptive methods during treatment with doxorubicin due to the potential toxicity of the medicine. If you wish to have children after treatment with Farmiblastina, you should consult your doctor about genetic counseling and fertility preservation options before starting treatment.
• If you need to be vaccinated while undergoing treatment with this medicine, as live or attenuated virus vaccines should not be administered, and the response to inactivated or killed vaccines may be reduced.
• If you are taking or have recently taken trastuzumab (a medicine used to treat certain types of cancer). Trastuzumab can remain in the body for up to 7 months. Since trastuzumab can affect the heart, you must not use Farmiblastina until 7 months after stopping trastuzumab. If Farmiblastina is used before this time, your heart function must be closely monitored.

If you are in any of the situations listed above, consult your doctor before using Farmiblastina.

Your doctor will regularly monitor your condition to check whether Farmiblastina is having the expected effect.

While you are being treated with Farmiblastina, you will have regular blood tests and periodic heart function assessments.

Other medicines and Farmiblastina

Inform your doctor or pharmacist if you are taking, have recently taken, or might need to take any other medicines.

The side effects may increase or the action of other medicines may be altered, such as those used for heart conditions, cancer treatment, antibiotics, female hormones, medicines that affect the immune system, and medicines used to treat epilepsy, as well as herbal medicines containing St. John's wort (Hypericum perforatum). Your doctor should also be informed about any vaccinations.

Pregnancy, breastfeeding, and fertility

If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.

You must not use Farmiblastina during pregnancy unless strictly necessary. Your doctor will inform you of the potential risks of using Farmiblastina during pregnancy.

Contraception in women of childbearing potential

You must always use an effective contraceptive method while receiving Farmiblastina and for at least 6.5 months after the last dose. Consult your doctor about contraceptive methods suitable for you and your partner.

Contraception in men

Men must always use effective contraceptive methods while receiving Farmiblastina and for at least 3.5 months after the last dose.

If you are breastfeeding, inform your doctor. Do not breastfeed during treatment with Farmiblastina or for at least 10 days after the last dose, as the medicine is excreted in breast milk.

Farmiblastina may cause loss of menstruation and infertility during treatment.

Both men and women should seek advice on fertility preservation before starting treatment.

Driving and use of machines

It is unknown whether Farmiblastina has any effect on the ability to drive or operate machinery. However, if you experience any symptoms affecting your ability to drive (such as weakness, nausea, or vomiting), you should not drive or operate machinery.

Farmiblastina contains methyl parahydroxybenzoate (E 218)

It may cause allergic reactions (possibly delayed) and, exceptionally, bronchospasm.

3. How to use Farmiblastina

Your doctor will determine the dose, duration of treatment, and the most appropriate route of administration for you, based on your condition and response to treatment.

Your doctor will inform you of the number of treatment cycles you need.

If you use more Farmiblastina than you should

Although unlikely, if you received more Farmiblastina than you should have, some of the known adverse effects of the medicine may occur. Consult your doctor immediately, as hospitalization may be required.

4. Possible adverse effects

Like all medicines, this medicine can cause side effects, although not everyone experiences them.

Very common side effects (may affect more than 1 in 10 patients):

• Changes in the electrocardiogram.
• Reduction in the number of white blood cells, especially neutrophils, red blood cells, and/or platelets in the blood.
• Inflammation of the mucosa of the mouth and/or gums, diarrhea, nausea, and vomiting.
• Redness, sensitivity, and/or peeling of the palms of the hands and soles of the feet (palmar-plantar erythrodysesthesia), hair loss (alopecia).
• Infection.
• Fever, weakness, chills.
• Asymptomatic decrease in the amount of blood pumped by the left ventricle of the heart, changes in liver enzyme levels (transaminases), weight gain.
• Loss of appetite.

Common side effects (may affect up to 1 in 10 patients):

• Loss of the heart's ability to pump blood (congestive heart failure), increased heart rate originating in the heart's sinus node.
• Inflammation of the esophagus (esophagitis), abdominal pain.
• Skin rash, skin and nail discoloration (hyperpigmentation), urticaria.
• Conjunctivitis (inflammation of the eye conjunctiva).
• Systemic infection.
• Reaction at the injection site.

Uncommon side effects (may affect up to 1 in 100 patients):

• Blockage of a blood vessel by material carried in the bloodstream.
• Abnormal heart rhythm, sensation of rapid or irregular heartbeat (palpitations), heart failure, which may cause difficulty breathing and swelling of the legs, cardiac arrest.

Rare side effects (may affect up to 1 in 1,000 patients):

• Bluish discoloration of the skin and mucous membranes due to low oxygen in the blood.
• Areas of thickened skin.

Side effects with unknown frequency (cannot be estimated from available data):

• Changes in heart rate (tachyarrhythmias), deterioration in the conduction of cardiac impulses from the atria to the ventricles (atrioventricular and bundle branch block).
• Keratitis (inflammation of the cornea), excessive production of tears (lacrimation).
• Mouth mucosa spots, gastric erosions, gastrointestinal tract bleeding, inflammation of the colon (colitis).
• Reddish discoloration of the urine for 1 or 2 days after administration.
• Itching, skin changes, skin sensitivity to light (photosensitivity), increased sensitivity of irradiated skin areas, dehydration, increased uric acid levels in blood (hyperuricemia).
• Acute lymphocytic leukemia, acute myeloid leukemia.
• Bleeding, blockage and inflammation of a blood vessel (thrombophlebitis), inflammation of blood vessels (phlebitis), hot flushes, shock.
• General malaise.
• Severe systemic allergic reaction (anaphylaxis).
• Absence of menstruation (amenorrhea), reduced number of spermatozoa (oligospermia), absence of spermatozoa (azoospermia).

Reporting of side effects

If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect not listed in this leaflet. You may also report them directly via the Spanish Pharmacovigilance System for Human Medicines: https://www.notificaram.es.

By reporting side effects, you can help provide more information on the safety of this medicine.

5. Conservation of Farmiblastina

Keep this medicine out of the sight and reach of children.

This medicine does not require special storage conditions.

Do not use this medicine after the expiry date stated on the label and on the packaging after EXP. The expiry date corresponds to the last day of the month indicated.

Do not use this medicine if you notice that the packaging is damaged or opened.

Medicines must not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of any unused medicines and their packaging. This will help protect the environment.

6. Additional Information

Composition of Farmiblastina

• The active substance is doxorubicin hydrochloride.
• The other components are methyl parahydroxybenzoate (E 218) and monohydrate lactose.

Appearance of the medicinal product and contents of the container

Each vial contains a reddish lyophilized powder.

Each vial contains 50 mg of doxorubicin hydrochloride.

It is available in a single presentation: 1 vial.

Marketing Authorization Holder and Manufacturer

Marketing Authorization Holder

Pfizer, S.L.

Avda. de Europa, 20 B

Parque Empresarial La Moraleja

28108 Alcobendas (Madrid)

Manufacturer

Latina Pharma S.p.A.

Via Murillo, 7

04013 Sermoneta (LT)

Italy

Date of the most recent review of this leaflet: May 2022

Detailed and up-to-date information on this medicinal product is available on the website of the Spanish Agency of Medicines and Health Products (AEMPS) http://www.aemps.gob.es